Screening Tests of Platelet Function: Update on Their Appropriate Uses for Diagnostic Testing

ABSTRACT

Global tests of platelet function are often used as screening tests during the laboratory investigation of individuals with suspected hemostatic defects. Because global tests of platelet function do not enable specific diagnosis of platelet disorders, they are normally performed as the first part of a two-step strategy that requires further testing with more specialized assays of platelet function to confirm or refute the diagnosis. The most commonly proposed rationale for testing global platelet function as a first-line investigation is that normal test results may exclude a diagnosis of platelet function disorder so that further specialized testing can be avoided. For this reason, global platelet function tests are usually initially performed at the same time as global assays of coagulation pathway function (prothrombin time and activated partial thromboplastin time, von Willebrand factor screening tests [VWF:Ag, VWF:RCo, and FVIII:C]) and measurement of platelet number. The most widely performed tests for screening platelet function disorders are currently the template bleeding time and the closure time within the Platelet Function Analyzer. These tests will therefore be considered in detail in this review, and we will discuss the limitations of these methods in screening individuals for platelet disorders.

KEYWORDS

Platelet disorders - platelet function testing - bleeding time - PFA-100 - platelet counting

REFERENCES

• 1 Hayward C P. Diagnostic approach to platelet function disorders.  Transfus Apheresis Sci. 2008;  38 65-76
• 2 Cattaneo M. Inherited platelet-based bleeding disorders.  J Thromb Haemost. 2003;  1 1628-1636
• 3 Quiroga T, Goycoolea M, Panes O et al.. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls.  Haematologica. 2007;  92 357-365
• 4 Zeidan A M, Kouides P A, Tara M A, Fricke W A. Platelet function testing: state of the art.  Expert Rev Cardiovasc Ther. 2007;  5 955-967
• 5 Laffan M, Brown S A, Collins P W et al.. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.  Haemophilia. 2004;  10 199-217
• 6 Bolton-Maggs P H, Perry D J, Chalmers E A et al.. The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.  Haemophilia. 2004;  10 593-628
• 7 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function.  Semin Thromb Hemost. 2009;  35 158-167
• 8 McGlasson D, Fritsma G A. Whole blood platelet aggregometry and platelet function testing.  Semin Thromb Hemost. 2009;  35 168-180
• 9 Varon D, Savion N. Impact Cone and Plate(let) Analyzer. In: Michelson, AD Platelets. San Diego, CA; Academic Press 2007: 535-544
• 10 Harrison P, Frelinger III A L, Furman M I, Michelson A D. Measuring antiplatelet drug effects in the laboratory.  Thromb Res. 2007;  120 323-336
• 11 Duke W W. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrahagic disease relieved by blood transfusion.  JAMA. 1910;  55 1185-1192
• 12 Mielke C H. Measurement of the bleeding time.  Thromb Haemost. 1984;  52 210-211
• 13 The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force . Guidelines on platelet function testing.  J Clin Pathol. 1988;  41 1322-1330
• 14 Jennings I, Woods T A, Kitchen S, Walker I D. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006.  J Clin Pathol. 2008;  61 950-954
• 15 Rodgers R P, Levin J. A critical reappraisal of the bleeding time.  Semin Thromb Hemost. 1990;  16 1-20
• 16 Peterson P, Hayes T E, Arkin C F et al.. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article.  Arch Surg. 1998;  133 134-139
• 17 Quiroga T, Goycoolea M, Munoz B et al.. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.  J Thromb Haemost. 2004;  2 892-898
• 18 Podda G M, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.  J Thromb Haemost. 2007;  5 2393-2398
• 19 Posan E, McBane R D, Grill D E, Motsko C L, Nichols W L. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice.  Thromb Haemost. 2003;  90 483-490
• 20 Quick A J. The bleeding time as a test of hemostatic function.  Am J Clin Pathol. 1975;  64 87-94
• 21 Kerenyi A, Schlammadinger A, Ajzner E et al.. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function.  Thromb Res. 1999;  96 487-492
• 22 Lind S E. The bleeding time does not predict surgical bleeding.  Blood. 1991;  77 2547-2552
• 23 Harrison P. Progress in the assessment of platelet function.  Br J Haematol. 2000;  111 733-744
• 24 Kratzer M A, Born G V. Simulation of primary haemostasis in vitro.  Haemostasis. 1985;  15 357-362
• 25 Kundu S K, Heilmann E J, Sio R et al.. Description of an in vitro platelet function analyzer–PFA-100.  Semin Thromb Hemost. 1995;  21(Suppl 2) 106-112
• 26 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.  J Lab Clin Med. 2001;  138 152-163
• 27 Moffat K A, Ledford-Kraemer M R, Nichols W L, Hayward C P. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association.  Thromb Haemost. 2005;  93 549-553
• 28 Harrison P, Robinson M S, Mackie I J et al.. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis.  Blood Coagul Fibrinolysis. 1999;  10 25-31
• 29 Heilmann E J, Kundu S K, Sio R et al.. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system.  Thromb Res. 1997;  87 159-164
• 30 Dyszkiewicz-Korpanty A, Quinton R, Yassine J, Sarode R. The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation.  J Thromb Haemost. 2004;  2 354-356
• 31 Harrison P. In vitro measurement of high-shear platelet adhesion and aggregation by the PFA-100.  Methods Mol Biol. 2004;  272 215-223
• 32 Hayward C P, Eikelboom J. Platelet function testing: quality assurance.  Semin Thromb Hemost. 2007;  33 273-282
• 33 Favaloro E J. Clinical utility of the PFA-100.  Semin Thromb Hemost. 2008;  34 709-733
• 34 Bock M, De Haan J, Beck K H et al.. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives.  Br J Haematol. 1999;  106 898-904
• 35 Sestito A, Sciahbasi A, Landolfi R et al.. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age.  Cardiologia. 1999;  44 661-665
• 36 Carcao M D, Blanchette V S, Dean J A et al.. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children.  Br J Haematol. 1998;  101 70-73
• 37 Dalby M C, Davidson S J, Burman J F, Davies S W. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser.  Platelets. 2000;  11 320-324
• 38 Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100.  Thromb Haemost. 2001;  85 369-370
• 39 Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients.  Stroke. 2003;  34 849-854
• 40 Hayward C P, Harrison P, Cattaneo M, Ortel T L, Rao A K. Platelet function analyser (PFA-100) closure time in the evaluation of platelet disorders and platelet function.  J Thromb Haemost. 2006;  4 312-319
• 41 Lasne D, Fiemeyer A, Chatellier G et al.. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft.  Thromb Haemost. 2000;  84 794-799
• 42 Pihusch R, Rank A, Gohring P et al.. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease.  J Hepatol. 2002;  37 548-555
• 43 Escolar G, Cases A, Vinas M et al.. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation.  Haematologica. 1999;  84 614-619
• 44 Pearson D A, Paglieroni T G, Rein D et al.. The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function.  Thromb Res. 2002;  106 191-197
• 45 Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults.  Br J Haematol. 2005;  130 3-10
• 46 Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use.  Clin Lab. 2005;  51 367-372
• 47 Favaloro E J. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review.  Semin Thromb Hemost. 2006;  32 537-545
• 48 Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis.  Transfusion. 2001;  41 56-60
• 49 Cattaneo M, Federici A B, Lecchi A et al.. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.  Thromb Haemost. 1999;  82 35-39
• 50 Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.  Haemophilia. 2001;  7 180-189
• 51 Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease.  Haematologica. 2002;  87 670
• 52 van Vliet H H, Kappers-Klunne M C, Leebeek F W, Michiels J J. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.  Thromb Haemost. 2008;  100 462-468
• 53 Mammen E F, Comp P C, Gosselin R et al.. PFA-100 system: a new method for assessment of platelet dysfunction.  Semin Thromb Hemost. 1998;  24 195-202
• 54 Harrison P, Robinson M, Liesner R et al.. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction.  Clin Lab Haematol. 2002;  24 225-232
• 55 Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary natured?.  J Thromb Haemost. 2004;  2 890-891
• 56 Harrison P, Segal H, Furtado C et al.. High incidence of defective high-shear platelet function among platelet donors.  Transfusion. 2004;  44 764-770
• 57 Karger R, Donner-Banzhoff N, Muller H H, Kretschmer V, Hunink M. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history-a systematic review and meta-analysis.  Platelets. 2007;  18 249-260
• 58 James A H, Lukes A S, Brancazio L R, Thames E, Ortel T L. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.  Am J Obstet Gynecol. 2004;  191 449-455
• 59 Philipp C S, Miller C H, Faiz A et al.. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time.  Haemophilia. 2005;  11 497-503
• 60 Acharya S, Barraclough J, Ibrahim M S et al.. The usefulness of the platelet function analyser (PFA-100) in screening for underlying bleeding disorders in women with menorrhagia.  J Obstet Gynaecol. 2008;  28 310-314
• 61 Jilma-Stohlawetz P, Hergovich N, Homoncik M et al.. Impaired platelet function among platelet donors.  Thromb Haemost. 2001;  86 880-886
• 62 Curvers J, Dielis A W, Heeremans J, van Wersch J W. Platelet function in whole-blood donors is impaired: the effects of painkillers.  Transfusion. 2007;  47 67-73
• 63 Koscielny J, Ziemer S, Radtke H et al.. A practical concept for preoperative identification of patients with impaired primary hemostasis.  Clin Appl Thromb Hemost. 2004;  10 195-204
• 64 Koscielny J, von Tempelhoff G F, Ziemer S et al.. A practical concept for preoperative management of patients with impaired primary hemostasis.  Clin Appl Thromb Hemost. 2004;  10 155-166
• 65 Bolton-Maggs P H, Chalmers E A, Collins P W et al.. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO.  Br J Haematol. 2006;  135 603-633
• 66 Harrison P, Briggs C, Machin S J. Platelet counting.  Methods Mol Biol. 2004;  272 29-46
• 67 Briggs C, Harrison P, Machin S J. Platelet counting. In: Michelson AD Platelets. San Diego, CA; Academic Press 2007: 475-483
• 68 Althaus K, Greinacher A. MYH9-related platelet disorders.  Semin Thromb Hemost. 2009;  35 189-203